戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 studied in the presence of a select group of cannabimimetics.
2                  These results indicate that cannabimimetics act presynaptically to inhibit the relea
3 ological assays for potential enhancement of cannabimimetic activities.
4 bind to the cannabinoid receptor and possess cannabimimetic activity yet are structurally dissimilar
5 sts in mouse behavioral assays indicative of cannabimimetic activity, including antinociception, hypo
6 e indole ring in compound 1 is essential for cannabimimetic activity.
7 n aliphatic hydroxyl (SAH) pharmacophore for cannabimimetic activity.
8 oups may be a characteristic requirement for cannabimimetic activity.
9 abinoid tetrad behaviors in mice, suggesting cannabimimetic activity.
10 ize harmful side effects of cannabinoids and cannabimimetic agents.
11 aS to G-proteins and were shown to be potent cannabimimetic agonists.
12 onship) models (CoMFA models 1 and 2) of the cannabimimetic (aminoalkyl)indoles (AAIs) for CB1 cannab
13 ether (2-AGE), and anandamide (AEA)] and the cannabimimetic aminoalkylindole WIN 55,212-2 (WIN) inhib
14                                          The cannabimimetic aminoalkylindole WIN 55,212-2 inhibited w
15 mmodate a wide range of structurally diverse cannabimimetic analogues including the AAIs.
16             Several analogs of an endogenous cannabimimetic, arachidonylethanolamide (anandamide), we
17 30 mg/kg over 2 hr, which resulted in robust cannabimimetic behavioral responses (hypolocomotion, ana
18  built a dose-prediction model that included cannabimimetic behavioral responses elicited by i.p. ver
19  and lipoxygenase and is mediated in part by cannabimimetic CB1 receptor, G protein, phosphoinositol
20                   Anandamide, the endogenous cannabimimetic compound, had an inconsistent effect on t
21 axant 2-arachidonoyl glycerol, an endogenous cannabimimetic derivative of arachidonic acid.
22                                 In contrast, cannabimimetics did not affect bicuculline-sensitive inh
23                                          The cannabimimetic drug Win55212-2 (100 nM) completely block
24                                          The cannabimimetic drug, Win 55212-2 (300 nM), inhibited FM1
25                                              Cannabimimetic drugs are of particular relevance to HAD
26                                              Cannabimimetic drugs did not protect cells from the dire
27                      These data suggest that cannabimimetic drugs may slow the progression of neurode
28                                              Cannabimimetic drugs prevented the recruitment of new sy
29 tiallodynic effects, possible tolerance, and cannabimimetic effects (e.g., hypothermia, catalepsy, CB
30 inistered in vivo, it induces only transient cannabimimetic effects as a result of its rapid cataboli
31 B2 receptors; however, unwanted CB1-mediated cannabimimetic effects limit clinical use.
32 B1 receptors with a significant reduction of cannabimimetic effects of CB1 agonists.
33 atory and neuropathic pain without producing cannabimimetic effects or physical dependence.
34 vo, ABM300 did not elicit anxiogenic-like or cannabimimetic effects, but it decreased novelty-induced
35 bition) and in vivo (anxiety-like behaviors, cannabimimetic effects, novel environment exploratory be
36 bition) and in vivo (anxiety-like behaviors, cannabimimetic effects, novel environment exploratory be
37 on over GAT211 while being devoid of adverse cannabimimetic effects.
38  to reduce excitotoxicity, we tested several cannabimimetics in a model of synaptically mediated neur
39  these Cannabis terpenes are multifunctional cannabimimetic ligands that provide conceptual support f
40  and to search for more selective and potent cannabimimetic ligands.
41 t may participate in maintaining a supply of cannabimimetic N-acylethanolamines during synaptic activ
42 action of the southern aliphatic hydroxyl of cannabimimetic pharmacophores with the CB1 and CB2 recep
43 12-2, a synthetic cannabinoid that possesses cannabimimetic properties, acts as a novel regulator of
44                                              Cannabimimetic responses (hypolocomotion, analgesia, and
45 onsumption of THC-E-gel triggered equivalent cannabimimetic responses in male and female mice, it pot
46 t preclinical experimental approach to study cannabimimetic responses triggered by voluntary consumpt
47 ding to cannabinoid receptors and of evoking cannabimimetic responses.
48 iallodynic efficacy, possible tolerance, and cannabimimetic side effects of repeated dosing with a CB
49 al body weight loss), but did not elicit any cannabimimetic side effects.
50 hic and inflammatory pain with minimal or no cannabimimetic side effects.
51 rawal efficacy, but is accompanied with some cannabimimetic side effects.
52 and the A current, were not modulated by the cannabimimetic WIN 55,212-2.
53                           Superfusion of the cannabimimetics WIN55212-2 or methanandamide onto CA1 ne